Siskin M, Economides M, Wise D
Cancers (Basel). 2025; 17(5).
PMID: 40075623
PMC: 11898528.
DOI: 10.3390/cancers17050774.
Wang Y, Yang R, Liu R, Yang R, Lin Z, He A
Front Immunol. 2024; 15():1415972.
PMID: 39664374
PMC: 11631746.
DOI: 10.3389/fimmu.2024.1415972.
Danielewski M, Walkowiak J, Wielgus K, Nowak J
Biomedicines. 2024; 12(11).
PMID: 39595122
PMC: 11592101.
DOI: 10.3390/biomedicines12112557.
Amacker A, Peng C, Jiang N, Sirivolu S, Higa N, Stachelek K
Int J Mol Sci. 2024; 25(21).
PMID: 39519212
PMC: 11545953.
DOI: 10.3390/ijms252111660.
Zhang W, Ge H, Wei Y, Gao J, Tian F, Zhou E
PLoS One. 2024; 19(10):e0312696.
PMID: 39466748
PMC: 11515967.
DOI: 10.1371/journal.pone.0312696.
Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.
Wilson T, Zishiri O
Cancer Rep (Hoboken). 2024; 7(10):e70016.
PMID: 39410867
PMC: 11480670.
DOI: 10.1002/cnr2.70016.
Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.
Wang M, Yan X, Dong Y, Li X, Gao B
PLoS Comput Biol. 2024; 20(5):e1012113.
PMID: 38728362
PMC: 11230636.
DOI: 10.1371/journal.pcbi.1012113.
Risk of Second Tumors in Retinoblastoma Survivors after Ionizing Radiation: A Review.
Figueiredo D, Marques I, Pires A, Cavaleiro C, Costa L, Castela G
Cancers (Basel). 2023; 15(22).
PMID: 38001596
PMC: 10670427.
DOI: 10.3390/cancers15225336.
Genetics in ophthalmology: molecular blueprints of retinoblastoma.
Markovic L, Bukovac A, Varosanec A, Slaus N, Pecina-Slaus N
Hum Genomics. 2023; 17(1):82.
PMID: 37658463
PMC: 10474694.
DOI: 10.1186/s40246-023-00529-w.
Mutation spectrum of retinoblastoma patients in Vietnam.
Linh D, Van Huy N, Nguyen P, Le Thi P, Tuan H, Nguyen T
Mol Genet Genomic Med. 2023; 11(11):e2244.
PMID: 37548407
PMC: 10655509.
DOI: 10.1002/mgg3.2244.
The complementary roles of genome-wide approaches in identifying genes linked to an inherited risk of colorectal cancer.
Ahmad O, Forsti A
Hered Cancer Clin Pract. 2023; 21(1):1.
PMID: 36707860
PMC: 9883872.
DOI: 10.1186/s13053-023-00245-5.
Risk of secondary tumours in patients with non-metastatic and metastatic human retinoblastoma.
Sadeghi R, Pirankuraim H, Javanshir S, Arabi M, Bereimipour A, Javanshir H
Eye (Lond). 2022; 37(11):2327-2334.
PMID: 36528757
PMC: 10366135.
DOI: 10.1038/s41433-022-02345-3.
β-asarone attenuates the proliferation, migration and enhances apoptosis of retinoblastoma through Wnt/β-catenin signaling pathway.
Bai S, Shao J, Bi C, Li F
Int Ophthalmol. 2022; 43(5):1687-1699.
PMID: 36372820
DOI: 10.1007/s10792-022-02566-1.
Normal and Neoplastic Growth Suppression by the Extended Myc Network.
Prochownik E, Wang H
Cells. 2022; 11(4).
PMID: 35203395
PMC: 8870482.
DOI: 10.3390/cells11040747.
Long intergenic non-protein coding RNA 115 (LINC00115) aggravates retinoblastoma progression by targeting microRNA miR-489-3p that downregulates 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2).
Ji F, Dai C, Xin M, Zhang J, Zhang Y, Liu S
Bioengineered. 2022; 13(3):5330-5343.
PMID: 35184643
PMC: 8973781.
DOI: 10.1080/21655979.2022.2037362.
Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y, Yam J, Chu W
Int J Mol Sci. 2021; 22(19).
PMID: 34639028
PMC: 8508856.
DOI: 10.3390/ijms221910687.
Targeting Loss in Cancers.
Linn P, Kohno S, Sheng J, Kulathunga N, Yu H, Zhang Z
Cancers (Basel). 2021; 13(15).
PMID: 34359636
PMC: 8345210.
DOI: 10.3390/cancers13153737.
The Rapidly Expanding Group of -Deleted Soft Tissue Tumors: An Updated Review.
Libbrecht S, Van Dorpe J, Creytens D
Diagnostics (Basel). 2021; 11(3).
PMID: 33802620
PMC: 8000249.
DOI: 10.3390/diagnostics11030430.
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.
Zhang X, Sjoblom T
Pharmaceuticals (Basel). 2021; 14(1).
PMID: 33450833
PMC: 7828287.
DOI: 10.3390/ph14010057.
Tumor-specific lytic path "hyperploid progression mediated death": Resolving side effects through targeting retinoblastoma or p53 mutant.
Hong F, Castro M, Linse K
World J Clin Oncol. 2020; 11(11):854-867.
PMID: 33312882
PMC: 7701912.
DOI: 10.5306/wjco.v11.i11.854.